Meridian Bioscience (VIVO) Tops Q1 EPS by 10c; Offers 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.21 -6.36%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $70.29 million.
GUIDANCE:
Meridian Bioscience sees FY2022 EPS of $1.10-$1.30, versus the consensus of $1.04. Meridian Bioscience sees FY2022 revenue of $315-330 million, versus the consensus of $288 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Cabot Corp. (CBT) Tops Q4 EPS by 7c, Beats on Revenue; Offers FY EPS Guidance
- Voyager Technologies, Inc. (VOYG) Misses Q3 EPS by 55c; Offer Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
